hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06277297 id: NP/2022/4583 briefTitle: Prognotic Role of CMR in Takotsubo Syndrome acronym: EVOLUTION overallStatus: RECRUITING date: 2022-11-09 date: 2026-11 date: 2032-11 date: 2024-02-26 date: 2024-02-28 name: University of Cagliari class: OTHER briefSummary: The primary objective of this observational registry is to develop a comprehensive clinical and imaging score (incorporating echocardiography and cardiac magnetic resonance data) that enhances risk stratification for patients with Takotsubo syndrome.
The design and rationale of this registry are available at 10.1097/RTI.0000000000000709 conditions: Takotsubo Cardiomyopathy conditions: Machine Learning conditions: Magnetic Resonance Imaging studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 350 type: ESTIMATED measure: All-cause mortality sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Cagliari status: RECRUITING city: Cagliari zip: 09100 country: Italy name: Riccardo Cau role: CONTACT phone: +393393493317 email: riccardo.cau@unica.it name: Luca Saba role: PRINCIPAL_INVESTIGATOR name: Riccardo Cau role: PRINCIPAL_INVESTIGATOR lat: 39.23054 lon: 9.11917 hasResults: False
nctId: NCT06277284 id: MG-K10-I-002 briefTitle: Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Healthy Adult Subjects overallStatus: ACTIVE_NOT_RECRUITING date: 2023-10-23 date: 2024-01-26 date: 2024-04 date: 2024-02-26 date: 2024-02-26 name: Shanghai Mabgeek Biotech.Co.Ltd class: OTHER_GOV name: The Second Hospital of Anhui Medical University briefSummary: Research Topics A randomized, open-label, parallel-group, phase I clinical trial comparing the pharmacokinetics of MG-K10 humanized monoclonal antibody in healthy adults conditions: Pharmacokinetics studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 60 type: ESTIMATED name: MG-K10 humanized monoclonal antibody injection (prefilled syringe) name: MG-K10 humanized monoclonal antibody injection（Penicillin bottle） measure: Pharmacokinetic: the maximum concentration (Cmax) measure: Pharmacokinetic: area under the curve of o~t measure: Pharmacokinetic: area under the curve of o~∞ measure: Safety evaluation index sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: The Second Affiliated Hospital of Anhui Medical University city: Hefei state: Anhui zip: 230061 country: China lat: 31.86389 lon: 117.28083 hasResults: False
nctId: NCT06277271 id: 1901611-9 briefTitle: E-cigarettes as a Harm Reduction Strategy overallStatus: RECRUITING date: 2023-06-20 date: 2024-02-20 date: 2024-03-20 date: 2024-02-26 date: 2024-02-26 name: Prisma Health-Upstate class: OTHER name: Clemson University briefSummary: E-cigarettes have emerged as an effective strategy for replacing cigarettes among smokers from the general population, but there is a dearth of studies investigating their utility in replacing cigarettes among smokers with opioid use disorder (OUD). This study aims to evaluate the feasibility and acceptability of implementing a cigarette harm reduction intervention involving e-cigarettes in office-based buprenorphine clinics. conditions: Smoking studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 30 type: ESTIMATED name: E-cigarette measure: Percentage of people who are eligible measure: Percentage of consented participants measure: Percentage of participants who report using the e-cigarette at least once a day measure: Percentage of participants with at least one puff of study e-cigarette measure: Percentage of daily diary completed measure: Cigarette dependence measured via the Fagerstrom test for nicotine dependence measure: Cigarette demand measured via the cigarette purchase task measure: Combustible cigarette smoking measure: Switching to e-cigarettes measure: Smoking reduction sex: ALL minimumAge: 21 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Prisma Health status: RECRUITING city: Greenville state: South Carolina zip: 29609 country: United States name: Alain Litwin, MD role: CONTACT phone: 864-455-5648 email: alain.litwin@prismahealth.org lat: 34.85262 lon: -82.39401 hasResults: False
nctId: NCT06277245 id: LK001303 briefTitle: A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis. overallStatus: RECRUITING date: 2024-02-06 date: 2025-09-30 date: 2025-11-30 date: 2024-02-26 date: 2024-03-20 name: Lynk Pharmaceuticals Co., Ltd class: INDUSTRY briefSummary: This is a randomized, double-blind study comparing LNK01001 to placebo in participants with moderately to severely atopic dermatitis who were candidates for systemic therapy (ie, patients with a history of inadequate response to topical treatments, those who were using a systemic treatment, or those for whom topical treatments are otherwise medically inadvisable).
The objective of this study is to evaluate the efficacy and safety of LNK01001 in adult patients with moderate to severe AD who are candidates for systemic therapy. conditions: Atopic Dermatitis studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 354 type: ESTIMATED name: LNK01001 name: Placebo measure: Eczema Area and Severity Index (EASI-75) at Week 16 measure: Investigator's Global Assessment (IGA) score of 0/1 at Week 16 measure: Worst-Itch Numeric Rating Scale (WI-NRS-4)-4 at Week 16 measure: Worst-Itch Numeric Rating Scale (WI-NRS-4)-4 at all visits other than Week 16. measure: Change from Baseline in Eczema Area and Severity Index at all visits. measure: Eczema Area and Severity Index (EASI 75) at all visits other than Week 16 sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Dermatological Hospital of Southern Medical University status: RECRUITING city: Guangzhou country: China name: Bing Yang, Doctor role: CONTACT phone: 020-87257353 email: yangbin101@hotmail.com lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06277232 id: HMV-2023-00504 id: 2022-05364-02 type: OTHER domain: The Swedish Ethical Review Authority briefTitle: Nutrition Care in Patients Living With Chronic Pain overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2026-06-30 date: 2026-10-31 date: 2024-02-26 date: 2024-03-22 name: Linkoeping University class: OTHER_GOV name: Ostergotland County Council, Sweden name: Fibromyalgia foundation briefSummary: The investigators' purpose is to develop and test the feasibility, usability, and satisfaction of the Diet4painrelief app as a platform for implementing nutrition care in a specialist pain rehabilitation clinic. The Diet4painrelief will consist of two components: a) a screening tool for nutrition status b) an individually tailored behavior change program aiming to improve the dietary habits and behaviors of patients living with chronic pain.
nctId: NCT06277219 id: LAT010-01 briefTitle: A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1) acronym: LIGHTSPEED-1 overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-12 date: 2027-03 date: 2024-02-26 date: 2024-02-26 name: Latticon Antibody Therapeutics, Inc class: INDUSTRY briefSummary: This is an open-label, multicenter, Phase 1/2, first-in-human (FIH), dose-escalation and cohort-expansion study of LAT010 to evaluate the safety, tolerability, immunogenicity, PK, PD, and antitumor activity in patients with advanced solid tumors. The study consists of 2 parts: Phase 1 dose-escalation and Phase 2 cohort expansion. conditions: Advanced Solid Tumor studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 150 type: ESTIMATED name: LAT010 name: LAT010 + ICI measure: Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) (Phase 1) measure: Incidence of changes in clinical laboratory values (Phase 1) measure: Incidence of dose-limiting toxicities (DLTs) (Phase 1) measure: Objective response rate (ORR) per RECIST 1.1 (Phase 2) measure: Maximum plasma concentration (Cmax) of LAT010 measure: Area under the plasma concentration-time curve (AUC) of LAT010 measure: Terminal phase half-life (t1/2) of LAT010 measure: Time to maximum concentration of LAT010 measure: Trough concentration of LAT010 measure: Volume of distribution of LAT010 measure: Clearance of LAT010 measure: ADA occurrence and titer in serum measure: Objective response rate (ORR) per RECIST 1.1 (Phase 1 ) measure: Duration of response (DOR) measure: Disease control rate (DCR) measure: Progression-free survival (PFS) measure: Overall survival (OS) measure: Incidence of AEs and SAEs measure: Epigenetic assessment of the proliferation and activation of CD4+ Treg cells, CD8+ T cells, and natural killer (NK) cells. measure: Optional flow cytometry assessment of the proliferation and activation of CD4+ Treg cells, CD8+ T cells, and NK cells. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Huntsman Cancer Institute city: Salt Lake City state: Utah zip: 84112 country: United States name: Jeana McKenney role: CONTACT phone: 801-213-8414 email: jeana.mckenney@hci.utah.edu name: Benjamin L Maughan, MD role: PRINCIPAL_INVESTIGATOR lat: 40.76078 lon: -111.89105 hasResults: False
nctId: NCT06277206 id: FAPIPDAC02 briefTitle: A Study Using 18F-FAPI PET to Evaluate Treatment Response in Pancreatic Adenocarcinoma overallStatus: COMPLETED date: 2021-08-04 date: 2023-11-19 date: 2024-02-10 date: 2024-02-26 date: 2024-02-26 name: Zhejiang University class: OTHER briefSummary: To explore the potential utility of 18F-FAPI-04 PET/CT for pathologic response evaluation to systemic treatment in PDAC conditions: 18F-FAPI conditions: Pancreas Adenocarcinoma conditions: Systemic Treatment conditions: Pathologic Response studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 59 type: ACTUAL name: 18F-FAPI PET/CT measure: Change of Maximum standardized uptake value measure: Change of Mean standardized uptake value measure: Maximum standardized uptake value measure: Mean standardized uptake value measure: Metabolic Tumor Volume measure: Total Lesion FAP expression measure: Change of Metabolic Tumor Volume measure: Change of Total Lesion FAP expression sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: First Affiliated Hospital, Medical College of Zhejiang University city: Hangzhou state: Zhejiang zip: 310003 country: China lat: 30.29365 lon: 120.16142 hasResults: False
nctId: NCT06277193 id: KonyaBeyhekimTRH briefTitle: Investigation of the Relationship Between Sarcopenia and Balance, Fear of Falling and Fall Risk in Older Female Patients overallStatus: COMPLETED date: 2020-11-03 date: 2022-12-01 date: 2023-09-28 date: 2024-02-26 date: 2024-02-26 name: Konya Beyhekim Training and Research Hospital class: OTHER_GOV briefSummary: This study (study type: cross-sectional) aims to investigate the relationship of sarcopenia level with balance, fear of falling and risk of falling in the elderly female population. In the first stage, 166 participants were divided into two groups: sarcopenia and non-sarcopenia. Afterwards, they were categorized according to sarcopenia level (probable sarcopenia group, sarcopenia group, severe sarcopenia group, group without sarcopenia) and comparisons were made between these subgroups. Then, they were evaluated with various scales and tests (in terms of balance, fear of falling and risk of falling). conditions: Sarcopenia studyType: OBSERVATIONAL observationalModel: ECOLOGIC_OR_COMMUNITY timePerspective: CROSS_SECTIONAL count: 166 type: ACTUAL name: valuation of balance status, fear of falling and risk of falling in patients non-sarcopenia. name: Evaluation of balance status, fear of falling and risk of falling in patients with probable sarcopenia. name: Evaluation of balance status, fear of falling and risk of falling in patients with sarcopenia. name: Evaluation of balance status, fear of falling and risk of falling in patients with severe sarcopenia. measure: Sociodemographic data measure: Berg Balance Scale(BBS) measure: Falls Efficacy Scale (FES) measure: Balance and Gait Assessment Scale measure: Biochemical data measure: Co-morbidities measure: Number of drugs measure: Basic activities of daily living (Katz) measure: Instrumental activities of living (Lawton-Brody; IADL) measure: Mini-nutritional evaluation (MNA-Short form) measure: Mini-mental state assessment (MMSE) measure: Yesavage Geriatric Depression Scale Short Form (GDS-SF) measure: FRAIL fragility index measure: Short physical performance battery (SPPB) measure: Timed up and go test (TUG) measure: The Tampa Scale for Kinesiophobia (TSK) sex: FEMALE minimumAge: 65 Years stdAges: OLDER_ADULT facility: Konya Beyhekim Training and Research Hospital Physical Medicine and Rehabilitation Clinic city: Selçuklu state: Konya country: Turkey lat: 37.8842 lon: 32.49222 hasResults: False
nctId: NCT06277180 id: TCR-FAPI for MTC Surgery briefTitle: 68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC overallStatus: RECRUITING date: 2023-10-01 date: 2025-12-31 date: 2027-12-31 date: 2024-02-26 date: 2024-02-26 name: Cancer Institute and Hospital, Chinese Academy of Medical Sciences class: OTHER name: Peking University name: Peking University Cancer Hospital & Institute briefSummary: This is a phase II clinical trial to evaluate the capability of 68Ga-labeled targeted covalent radiopharmaceutical (TCR) fibroblast activation protein inhibitor (FAPI) PET/CT to guide the surgical treatment of medullary thyroid carcinoma (MTC). The surgical extent of MTC is determined based on the lesion range revealed by 68Ga-TCR-FAPI PET/CT, with the main endpoint being 1-month post-surgical calcitonin level. conditions: Medullary Thyroid Cancer conditions: Prositron Emission Tomography conditions: Fibroblast Activation Protein Inhibitor conditions: Surgery studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: Surgery name: Surgery measure: 1-month post-surgery calcitonin level measure: 2-year event free survival measure: Ratio of patient that change surgical plan measure: Accuracy, sensitivity, specificity of 68Ga-TCR-FAPI PET/CT in identifying MTC lesions sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College status: RECRUITING city: Beijing zip: 100021 country: China name: Shaoyan Liu, M.D. role: CONTACT phone: 0086-010-87787190 email: shaoyanliu.bj@263.net lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06277167 id: KXZY-GB05-101 briefTitle: A Phase I Study of Human Interferon Alfa 1b Inhalation Solution in Healthy Participants overallStatus: ACTIVE_NOT_RECRUITING date: 2023-01-07 date: 2024-05-21 date: 2024-05-21 date: 2024-02-26 date: 2024-02-26 name: Kexing Biopharm Co., Ltd. class: INDUSTRY name: Guoxin Pharmaceutical Technology (Beijing) Co., Ltd. name: The Third Hospital of Changsha name: Beijing SSYP Data Technology Development Co.,Ltd. name: United-Power Pharma Tech（Shanghai）Co., Ltd. briefSummary: A Randomized, Double-Blind, Placebo-Controlled Phase-I Clinical Study to Evaluate the Tolerability, Safety and PK Profiles of Human interferon alfa 1b inhalation solution in Healthy Adult Subjects after Administration of Single Ascending Doses and Multiple Ascending Doses conditions: Healthy Participants studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 35 type: ACTUAL name: Human interferon alfa 1b inhalation solution name: Human interferon alfa 1b inhalation solution placebo name: Human interferon alfa 1b inhalation solution name: Human interferon alfa 1b inhalation solution placebo measure: TEAEs measure: (ADRs) measure: (SAE) measure: TEAEs that lead to subject discontinuation from the study measure: Cmax After a Single Dose of GB05 Drug Product measure: Tmax After a Single Dose of GB05 Drug Product measure: AUC0-t and AUC0-inf After a Single Dose of GB05 Drug Product measure: t1/2 After a Single Dose of GB05 Drug Product measure: Ke After a Single Dose of GB05 Drug Product measure: Vd After a Single Dose of GB05 Drug Product measure: MRT After a Single Dose of GB05 Drug Product measure: CL After a Single Dose of GB05 Drug Product measure: Cmax,ss After Multiple Doses of GB05 Drug Product measure: Cmin,ss After Multiple Doses of GB05 Drug Product measure: Css_av After Multiple Doses of GB05 Drug Product measure: DF After Multiple Doses of GB05 Drug Product measure: (Cmax,ss-Cmin,ss)/Cmin,ss After Multiple Doses of GB05 Drug Product measure: ADA measure: NAb sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: The Third Hospital of Changsha city: Changsha country: China lat: 28.19874 lon: 112.97087 hasResults: False
nctId: NCT06277154 id: MASCT-I-2004 briefTitle: MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2026-02 date: 2027-02 date: 2024-02-26 date: 2024-02-26 name: HRYZ Biotech Co. class: INDUSTRY briefSummary: This study will evaluate the safety and efficacy of MASCT-I combined with Doxorubicin and Ifosfamide for first-line treatment in patients with advanced soft tissue sarcoma. conditions: Leiomyosarcoma conditions: Liposarcoma conditions: Synovial Sarcoma conditions: Angiosarcoma conditions: Undifferentiated Pleomorphic Sarcoma conditions: Epithelioid Sarcoma conditions: Malignant Peripheral Nerve Sheath Tumors conditions: Fibrosarcoma conditions: Pleomorphic Rhabdomyosarcoma conditions: Endometrial Stromal Sarcoma conditions: Desmoplastic Small Round Cell Tumor studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 148 type: ESTIMATED name: MASCT-I name: Doxorubicin name: Ifosfamide measure: Progression-Free Survival (PFS) measure: Overall Survival (OS) measure: Objective Response Rate (ORR) measure: Disease Control Rate (DCR) measure: Duration of response (DoR) measure: Adverse events and serious adverse events measure: Adverse events and serious adverse events related to MASCT-I measure: Rate and severity of clinically-significant abnormalities in laboratory testings measure: Immune response to tumor-associated antigens sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sun Yat-sen University Cancer Center city: Guangzhou country: China name: Xing Zhang role: CONTACT email: zhangxing@sysucc.org.cn name: Xing Zhang role: PRINCIPAL_INVESTIGATOR lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06277141 id: M230742 briefTitle: The Vitality Mammography Messaging Study acronym: VMS overallStatus: ACTIVE_NOT_RECRUITING date: 2023-09-27 date: 2024-03-31 date: 2024-03-31 date: 2024-02-26 date: 2024-03-22 name: Wits Health Consortium (Pty) Ltd class: OTHER name: Discovery Vitality briefSummary: The investigators will be conducting a randomized controlled trial amongst members of a Wellness Program to test receipt of mammogram using the Whatsapp social media platform and testing various messages. conditions: Breast Cancer Female studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized controlled trial primaryPurpose: SCREENING masking: NONE count: 6665 type: ESTIMATED name: Standard message name: Radiology booking site link. name: Radiology practice telephone numbers name: Radiology site link and telephone numbers measure: Comparison of mammography screening rates using WhatsApp sex: FEMALE minimumAge: 50 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Witwatersrand city: Johannesburg state: Gauteng country: South Africa lat: -26.20227 lon: 28.04363 hasResults: False
nctId: NCT06277115 id: BASEC Nr. 2020-02002 briefTitle: Acute and Long-term Effects of CPAP in OSA overallStatus: RECRUITING date: 2021-02-01 date: 2024-07 date: 2024-12 date: 2024-02-26 date: 2024-02-28 name: University of Zurich class: OTHER briefSummary: Two-phase interventional non-inferiority trial (phase 1: at least 8 weeks of CPAP; phase 2: 2 weeks of CPAP withdrawal) including 32 patients with moderate to severe OSA to compare the physiological consequences of a short-term CPAP withdrawal to the changes in previously untreated OSA. The trial has been designed as a validation of the CPAP-withdrawal model. Baseline in-laboratory sleep studies will be performed prior to CPAP initiation, after 6-8 weeks on CPAP (treatment effect) and following 2 weeks of CPAP therapy withdrawal (withdrawal effect, effect of OSA recurrence). conditions: Obstructive Sleep Apnea of Adult studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Two-phase intervention: several weeks of CPAP therapy followed by two weeks CPAP therapy withdrawal primaryPurpose: TREATMENT masking: NONE count: 32 type: ESTIMATED name: Continuous positive airway pressure (CPAP) measure: Nocturnal systolic blood pressure measure: Epworth Sleepines Scale Score (ESS) measure: 48h, 24h, diurnal and nocturnal systolic and diastolic blood pressure measure: Office systolic and diastolic blood pressure measure: 48h, 24h, diurnal, nocturnal and office heart rate measure: Heart rate variability in the time and frequency domain (CV, RMSSD, pRR50, LF, HF, LF/HF) measure: Blood pressure variability (BPV, systolic and diastolic) measure: Baroreflex sensitivity (BRS) measure: Arterial stiffness measure: Measures of nocturnal hypoventilation (median and maximal transcutaneous partial pressure of CO2 = tcpCO2) measure: Measures of nocturnal hypoxaemia (mean nocturnal oxygen saturation = ¢SpO2) measure: Measures of nocturnal hypoxaemia (time spent with SpO2 below 90% = t<90) measure: Measures of nocturnal hypoxaemia (hypoxic burden) measure: Measures of OSA severity (apnoea-hypopnoea-index) measure: Measures of OSA severity (oxygen-desaturation index) measure: Sleepiness (Stanford Sleepiness Scale (SSS)) measure: Fatigue (fatigue severity scale (FSS)) measure: Disease-specific quality of life (Functional Outcomes of Sleep Questionnaire (FOSQ)) measure: Superoxide dismutase measure: Urinary catecholamines measure: Pulse rise index (>6 beats per minute) measure: Nocturnal oxymetry measures (¢SpO2, t<90, ODI-3%, ODI-4%) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Zurich status: RECRUITING city: Zurich zip: 8091 country: Switzerland name: Esther I Schwarz, MD role: CONTACT phone: 0041442553828 email: estherirene.schwarz@usz.ch name: Joël J Herzig role: CONTACT email: joel.herzig@usz.ch lat: 47.36667 lon: 8.54999 hasResults: False
nctId: NCT06277102 id: Music pain FHF briefTitle: Effects of Music on Acute Postoperative Pain Intensity and Mobility After Fragility Hip Fracture overallStatus: RECRUITING date: 2024-01-26 date: 2024-06-01 date: 2024-06-01 date: 2024-02-26 date: 2024-02-26 name: Hospital Authority, Hong Kong class: OTHER_GOV briefSummary: Music has been proven to be beneficial in postoperative care by reducing pain. The effects of music listening to reduce pain postoperatively are well studied among cases undergoing elective orthopaedic surgery. No study has been conducted focusing on pain control among cases with fragility hip fractures in an acute ward setting with non-schedule non-elective orthopaedic operation.